Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1- mediated autoimmune diseases

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 1117-1124

  Bielekova, Bibiana ^a   Lincoln, Anne ^a   McFarland, Henry ^a   Martin, Roland ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CILOSTAMIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; ATOPY; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG MECHANISM; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034650812     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.1117     Document Type: Article

References (48)

1. Teixeira, M. M., R. W. Gristwood, N. Cooper, and P. G. Hellewell. 1997. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18:164.
2. Ekholm, D., B. Hemmer, G. Gao, M. Vergelli, R. Martin, and V. Manganiello. 1997. Differential expression of cAMP cyclic nucleotide phosphodiesterase PDE3 and PDE4 activities in human T cell clones specific for myelin basic protein. J. Immunol. 159:1520.
3. Bloom, T. J., and J. A. Beavo. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93:14188.
4. Marcoz, P., A. F. Prigent, M. Lagarde, and G. Nemoz. 1993. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44:1027.
5. Sommer, N., R. Martin, H. F. McFarland, L. Quigley, D. Scott, B. Cannella, C. S. Raine, P. A. Löschmann, and M. K. Racke. 1997. Therapeutic potential of selective cyclic nucleotide phosphodiesterase (ype 4 inhibition in the treatment of chronic experimental autoimmune disease. J. Neuroimmunol. 79:54.
6. Eigler, A., B. Siegmund, U. Emmerich, K. H. Baumann, G. Hartmann, and S. Endres. 1998. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukocyte Biol. 63:101.
7. + T cells while decreasing IL-2 release and NF-AT induction. Int. Immunol. 6:1333.
8. Rott, O., E. Cash, and B. Fleischer. 1993. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1745.
9. Sommer, N., P. A. Loschmann, G. H. Northoff, M. Weller, A. Steinbrecher, J. P. Steinbach, R. Lichtenfels, R. Meyermann, A. Riethmuller, A. Fontana, et al. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:244.
10. Genain, C. P., T. Roberts, R. L. Davis, M.-H. Nguyen, A. Uccelli, D. Faulds, Y. Li, J. Hedgpeth, and S. L. Hauser. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92:3601.
11. Ross, S. E., R. O. Williams, L. J. Mason, C. Mauri, L. Marino-Mutafchieva, A.-M. Malfait, R. N. Maini, and M. Feldmann. 1997. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J. Immunol. 159:6253.
12. Nyman, U., A. Mussener, E. Larsson, J. Lorentzen, and L. Klareskog. 1997. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin. Exp. Immunol. 108:415.
13. Panitch, H. S., R. L. Hirsch, A. S. Haley, and K. P. Johnson. 1987. Exacerbations of multiple sclerosis in patients treated with y interferon. Lancet 1:893.
14. Rieckmann, P., F. Weber, A. Günther, S. Martin, A. Bitsch, A. Broocks, B. Kitze, T. Weber, T. Börner, and S. Poser. 1996. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64:193.
15. Pette, M., P. A. Muraro, D. F. Pette, H. Dinter, H. F. McFarland, and R. Martin. 1999. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. J. Neuroimmunol. 98:147.
16. Essayan, D. M., A. Kagey-Sobotka, L. M. Lichtenstein, and S. K. Huang. 1997. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 282:505.
17. Deibler, G. E., R. E. Martenson, and M. W. Kies. 1972. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep. Biochem. 2:139.
18. Muraro, P. A., M. Vergelli, M. Kalbus, D. E. Banks, J. W. Nagle, L. R. Tranquill, G. T. Nepom, W. E. Biddison, H. F. McFarland, and R. Martin. 1997. Immunodominance of a low-affinity major histocompatibility complex- binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 100:339.
19. Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122.
20. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues, J. Exp. Med. 178:1309.
21. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J. Exp. Med. 172:95.
22. + T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J. Virol. 70:4787.
23. Sorensen, T. L., M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, V. A. Folcik, S. Qin, J. Rottman, F. Sellebjerg, R. M. Stricter, et al. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:807.
24. Chan, S. C., S. H. Li, and J. M. Hanifin. 1993. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J. Invest. Dermatol. 100:681.
25. Maida, E., and W. Kristoferitsch. 1981. Cyclic adenosine 3′,5′ monophosphate in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. 225:145.
26. Maciejek, Z., A. Jurkowski, and H. Chmielewski. 1985. cAMP and cGMP in the cerebrospinal fluid of patients with multiple sclerosis. Neurol. Neurochir. Pol. 19:471.
27. Lombardi, M. S., A. Kavelaars, M. Schedlowski, J. W. Bijlsma, K. L. Okihara, M. Van de Pol, S. Ochsmann, C. Pawlak, R. E. Schmidt, and C. J. Heijnen. 1999. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J. 13:715.
28. Kammer, G. M., I. U. Khan, and C. J. Malemud. 1994. Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J. Clin. Invest. 94:422.
29. Laxminarayana, D., I. U. Khan, N. Mishra, I. Olorenshaw, K. Tasken, and G. M. Kammer. 1999. Diminished levels of protein kinase A Rlα0 and Rlβ transcripts and proteins in systemic lupus erythematosus T lymphocytes. J. Immunol. 162:5639.
30. Hanifin, J. M., and S. C. Chan. 1995. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J. Invest. Dermatol. 105:84S.
31. Chan, S. C., and J. M. Hanifin. 1993. Differential inhibitor effects on cyclic adenosine monophosphate- phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med. 121:44.
32. Holden, C. A., S. C. Chan, and J. M. Hanifin. 1986. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J. Invest. Dermatol. 87:372.
33. Vergelli, M., V. Pinet, A. B. Vogt, M. Kalbus, M. Malnati, P. Riccio, E. O. Long, and R. Martin. 1997. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. Eur. J. Immunol. 27:941.
34. Weber, F., T. Polak, A. Gunther, B. Kubuschok, J. Janovskaja, A. Bitsch, S. Poser, and P. Rieckmann. 1998. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing- remitting multiple sclerosis. Ann. Neurol. 44:27.
35. Jiang, H., B. Bielekova, H. Okazaki, K. Clarence-Smith, J. K.P., G. Bergey, R. Martin, and S. Dhib-Jalbut. 1999. The effect of vesnarinone on TNFα production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. J. Neuroimmunol 97:134.
36. Baroja, M. L., L. B. Cieslinski, T. J. Torphy, R. L. Wange, and J. Madrenas. 1999. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J. Immunol. 162:2016.
37. + T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297.
38. Kuchroo, V. K., M. Prabhu Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
39. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
40. Svenningsson, A., L. Dotevall, S. Stemme, and O. Andersen. 1997. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J. Neuroimmunol. 75:59.
41. Sellebjerg, F., J. Jensen, and L. P. Ryder. 1998. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J. Neuroimmunol. 84:179.
42. + B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J. Clin. Invest. 99: 2664.
43. Ivashkiv, L. B., A. Ayres, and L. H. Glimcher. 1994. Inhibition of IFN-γ induction of class II MHC genes by cAMP and prostaglandins. Immunopharmacology 27:67.
44. Navikas, V., D. Matusevicius, M. Soderstrom, R. Pirskanen, S. Fredrikson, and H. Link. 1998. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-γ and TNF-α mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin. Neuropharmacol. 21:236.
45. Denis, D., and D. Riendeau. 1999. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Eur. J. Pharmacol. 367:343.
46. Chini, C. C., J. P. Grande, E. N. Chini, and T. P. Dousa. 1997. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4: regulation of superoxidation and autogenesis. J. Biol. Chem. 272:9854.
47. Verghese, M. W., R. T. McConnell, J. M. Lenhard, L. Hamacher, and S. L. Jin. 1995. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47:1164.
48. Bielekova B., P. A. Munro, L. Golestaneh, J. Pascal. H. F. McFarland, and R. Martin. 1999. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7. J. Neuroimmunology. In press.